$NVS

$NVS Ceo on Cnbc…

$NVS down in ah…

$NVS says Phase 3 trial for Cardiovascular disease did not meet primary endpoint…

$NVS remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials…